Krzyzanski Wojciech, Woo Sukyung, Jusko William J
Department of Pharmaceutical Sciences, State University of New York, Buffalo, New York 14260, USA.
J Pharmacokinet Pharmacodyn. 2006 Apr;33(2):125-66. doi: 10.1007/s10928-006-9007-3. Epub 2006 Mar 25.
Indirect pharmacodynamic response (IDR) models were developed for agents which alter the generation of cell populations with arbitrary lifespan distributions. These models extend lifespan based IDR models introduced previously [J. Pharmacokinet. Biopharm. 27: 467, 1999] for cell populations with the same lifespan ("delta" distribution). Considered are cell populations exhibiting time-invariant lifespan distributions described by the probability density function l(tau). It is assumed that cell response (R) is produced at a zero-order rate (kin(t)) and is eliminated from the population when the cell lifespan expires. The cell loss rate is calculated as kinl(t), where '' denotes the convolution operator. Therapeutic agents can stimulate or inhibit production rates according to the Hill function: 1 +/- H(C(t)) where H(C(t)) contains the capacity (Smax) and potency (SC50) parameters and C(t) is a pharmacokinetic function. The production rate is kin(t) = kin.[ 1+/-H(C(t))]. The operational model is dR/dt = kin(t)-kin*l(t) with the baseline condition R0 = kin.TR, where TR is the mean lifespan. Single populations as well as populations with precursors were examined by simulation to establish the role of lifespan distribution parameters (mean and standard deviation) in controlling the response vs. time profile. Estimability of parameters was assessed. Numerical techniques of solving differential equations with the convolution integral were proposed. In addition, the models were applied to literature data to describe the stimulatory effects of single doses of recombinant human erythropoietin on reticulocytes in blood. The estimates of Smax and SC50 for these agents were obtained along with means and standard deviations for reticulocyte lifespan distributions. The proposed models can be used to analyze the pharmacodynamics of agents which alter natural cell production yielding parameters describing their efficacy and potency as well as means and standard deviations for cell lifespan distributions.
针对那些改变具有任意寿命分布的细胞群体生成的药物,开发了间接药效学反应(IDR)模型。这些模型扩展了之前[《药代动力学与生物药剂学杂志》27: 467, 1999]引入的基于寿命的IDR模型,用于具有相同寿命(“δ”分布)的细胞群体。所考虑的是由概率密度函数l(τ)描述的具有时间不变寿命分布的细胞群体。假设细胞反应(R)以零级速率(kin(t))产生,并在细胞寿命结束时从群体中消除。细胞损失率计算为kinl(t),其中“”表示卷积算子。治疗药物可根据希尔函数刺激或抑制生成速率:1 ± H(C(t)),其中H(C(t))包含容量(Smax)和效力(SC50)参数,C(t)是药代动力学函数。生成速率为kin(t) = kin.[1 ± H(C(t))]。操作模型为dR/dt = kin(t) - kin*l(t),基线条件为R0 = kin.TR,其中TR是平均寿命。通过模拟研究了单群体以及有前体的群体,以确定寿命分布参数(均值和标准差)在控制反应与时间曲线中的作用。评估了参数的可估计性。提出了用卷积积分求解微分方程的数值技术。此外,将这些模型应用于文献数据,以描述单剂量重组人促红细胞生成素对血液中网织红细胞的刺激作用。获得了这些药物的Smax和SC50估计值以及网织红细胞寿命分布的均值和标准差。所提出的模型可用于分析改变天然细胞生成的药物的药效学,得出描述其疗效和效力的参数以及细胞寿命分布的均值和标准差。